DeepMed Research

Minervax ApS

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Holding

Established: 2010-01-01

Employees: 1

Market Cap: -

Website: http://www.minervax.com

Clinical Trials

A Follow-up Trial of GBS-NN/NN2 Vaccine in Healthy Pregnant Women

Phase 2

Recruiting

Conditions: Streptococcus Agalactiae Infection
Neonatal Sepsis
Pneumonia
Meningitis
Neonatal Infection
Gram-Positive Bacterial Infections
Bacterial Infections
Bacterial Infections and Mycoses
Infections

Interventions: Biological: GBS-NN/NN2 vaccine

First Posted Date: 2024-09-19

Last Posted Date: 2025-04-04

Lead Sponsor: Minervax ApS

Target Recruit Count: 338

Registration Number: NCT06592586

Locations: 🇿🇦
Sefako Makgatho Health Sciences University, Medunsa Clinical Research Unit (MeCRU), Ga-Rankuwa, Gauteng, South Africa
🇩🇰
Sygehus Lillebælt - Kolding Sygehus, Kolding, Syddanmark, Denmark
🇩🇰
Aarhus Universitetshospital, Aarhus N, Midtjylland, Denmark

GBS-NN/NN2 (50 µg of Each Fusion Protein [GBS-NN and GBS-NN2] in Combination With 500 µg Aluminum as Alhydrogel®) Given With and Without the Tdap Vaccine in Healthy Non-pregnant Women 18 to 49 Years of Age

Phase 2

Not yet recruiting

Conditions: Streptococcus Agalactiae Infection

Interventions: Drug: GBS-NN/NN2 vaccine
Drug: Tdap vaccine
Drug: Placebo

First Posted Date: 2024-07-10

Last Posted Date: 2024-07-10

Lead Sponsor: Minervax ApS

Target Recruit Count: 564

Registration Number: NCT06494475

A Follow up Study of Group B Streptococcus (GBS)-NN/NN2 Vaccine in Healthy Volunteers

Conditions: Group B Streptococcus Infection

Interventions: Biological: GBS-NN/NN2

First Posted Date: 2024-02-28

Last Posted Date: 2025-05-15

Lead Sponsor: Minervax ApS

Target Recruit Count: 55

Registration Number: NCT06280157

Locations: 🇬🇧
Simbec-Orion Clinical Pharmacology, Merthyr Tydfil, Pentrebach Merthyr Tydfil CF48 4DR, United Kingdom

Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Doses of GBS Vaccine in Elderly Participants

Phase 1

Completed

Conditions: Group B Streptococcal Infections

Interventions: Biological: Placebo
Biological: GBS-NN/NN2

First Posted Date: 2023-03-23

Last Posted Date: 2024-05-29

Lead Sponsor: Minervax ApS

Target Recruit Count: 90

Registration Number: NCT05782179

Locations: 🇧🇪
University Hospital Ghent - Centrum voor Vaccinologie (CEVAC) department, Ghent, Belgium

Immunogenicity and Safety of GBS-NN/NN2 in Pregnant Women

Phase 2

Completed

Conditions: Group B Streptococcal Infection

Interventions: Biological: GBS-NN/NN2 Vaccine
Biological: Placebo

First Posted Date: 2021-12-13

Last Posted Date: 2025-01-13

Lead Sponsor: Minervax ApS

Target Recruit Count: 269

Registration Number: NCT05154578

Locations: 🇬🇧
St George's University Hospital, London, United Kingdom
🇩🇰
Institut for Regional Sundhedsforskning, Kolding, Denmark
🇿🇦
Mecru Clinical Research Unit (MeCRU), Pretoria, South Africa

and more 7 locations

Study to Assess a Booster Dose of GBS-NN/NN2 Vaccine

Phase 1

Completed

Conditions: Group B Streptococcus Infection

Interventions: Biological: GBS-NN/NN2

First Posted Date: 2021-08-13

Last Posted Date: 2024-10-10

Lead Sponsor: Minervax ApS

Target Recruit Count: 27

Registration Number: NCT05005247

Locations: 🇬🇧
Simbec Clinical Pharmacology, Merthyr Tydfil, Wales, United Kingdom

Study of a Group B Streptococcus Vaccine in Pregnant Women Living With HIV and in Pregnant Women Who do Not Have HIV

Phase 2

Completed

Conditions: Group B Streptococcal Infection

Interventions: Biological: GBS-NN/NN2
Biological: Placebo

First Posted Date: 2020-10-22

Last Posted Date: 2023-08-23

Lead Sponsor: Minervax ApS

Target Recruit Count: 205

Registration Number: NCT04596878

Locations: 🇺🇬
MUJHU Research Collaboration/MUJHU Care Ltd, Kawempe National Referral Hospital, Kawempe, Uganda
🇿🇦
Empilweni Services and Research Unit (ESRU), Rahima Moosa Mother and Child Hospital, Johannesburg, South Africa
🇿🇦
University of the Witwatersrand, Johannesburg (Respiratory and Meningeal Pathogens Research unit), Johannesburg, South Africa

Group B Streptococcus Vaccine in Healthy Females

Phase 1

Completed

Conditions: Group B Strep Infection

Interventions: Biological: Placebo GBS-NN/NN2 with Alhydrogel® 25
Biological: Placebo GBS-NN/NN2 with Alhydrogel® 50
Biological: GBS-NN/NN2 with Alhydrogel® 50
Biological: GBS-NN/NN2 with Alhydrogel® 25

First Posted Date: 2019-01-16

Last Posted Date: 2021-02-02

Lead Sponsor: Minervax ApS

Target Recruit Count: 60

Registration Number: NCT03807245

Locations: 🇬🇧
Simbec Research Limited, Merthyr Tydfil, Wales, United Kingdom

Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non-pregnant Women 18-40 Years of Age.

Phase 1

Completed

Conditions: Infection by Streptococcus Group B

Interventions: Biological: GBS-NN vaccine

First Posted Date: 2015-06-02

Last Posted Date: 2021-01-14

Lead Sponsor: Minervax ApS

Target Recruit Count: 240

Registration Number: NCT02459262

Locations: 🇬🇧
Biokinetic Europ Ltd, Belfast, United Kingdom

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy